Milner Therapeutics Institute

Our Affiliated Company network now includes 70 organisations that bring diverse expertise and resource to the Milner community. We are delighted to have recently welcomed the following new affiliated companies to our network: 🌻 Collaborative Drug Discovery - CDD Vault provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organise, share and analyse both biological and chemical data, and to collaborate with partners through a straightforward and secure web interface. 🌻 Scale Biosciences is at the forefront of a new era in single cell research, providing scientists with the tools they need to push the boundaries of biological discovery. Our innovative platforms combine accessibility, flexibility, and scalability, allowing researchers to design experiments that fit their unique scientific objectives without compromising on quality or results. 🌻 TTP plc is a leading product and technology development company based in Cambridge, UK. We work on a diverse range of projects in life science and healthcare, encompassing advanced diagnostic systems, cell therapy manufacturing, drug discovery tools, multi-omics, drug delivery systems, biosensing, surgical/imaging technology and digital healthcare solutions. Find out more about our affiliate network at https://lnkd.in/drbWmrT

We're delighted that Rachel Watkins – Director of Experimental Biology at CoSyne Therapeutics – will present at ELRIG UK's Drug Discovery 2024! Cosyne are one of the companies in our bio-incubator Frame Shift. They are working on creating a platform for drug discovery in under-served brain diseases, based on high-quality scientific data integrated with AI and machine learning. Learn more about Frame Shift 👉 https://lnkd.in/dwmxHYgB Learn more about Cosyne 👉 https://www.cosyne.com Register 👉 https://lnkd.in/ePmtmfN9

Our Affiliated Company network now includes 70 organisations that bring diverse expertise and resource to the Milner community. We are delighted to have recently welcomed the following new affiliated companies to our network: 🌻 Cumulus Oncology connects the dots between oncology research, drug discovery, development, commercialisation, and value creation to accelerate drug development programs, create new companies, and co-develop or license attractive assets/targets in oncology. 🌻 Oncimmune is a leading autoantibody profiling company that enables precision medicine, focusing on the rapidly growing fields of immuno-oncology, autoimmune diseases, infectious diseases, and longevity. By partnering with global pharmaceutical and biotech companies and CROs, Oncimmune discovers novel biomarkers to develop targeted and effective therapies for immune-mediated diseases. 🌻 Portal Biotech is defining a new category of proteomics and metabolomics solutions, characterized by the rapid and high-throughput analysis of single molecules with an accessible desktop device. Building on the Maglia Method for nanopore translocation, our technology provides detailed information about full-length proteins and small molecules, their mutations and post-translational modifications, without lengthy or cumbersome sample preparation. 🌻 Stratosvir Limited is a UK-based early stage company that is engineering viruses to treat solid tumours. Viral immunotherapy is a new modality and has shown promise in the clinic but still requires direct injection intra-tumourally, which limits its use and market. Stratosvir is engineering the viruses for intravenous injection to overcome this barrier and bring the modality into the mainstream. Find out more about our affiliate network at https://lnkd.in/drbWmrT

Save the date! 👀👇 Milner Seminars – Focus on respiratory disease 🗓️ Thursday, 26th September 📍In person at the Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus ⏰ 4pm Mark Toshner, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge ⏰ 4.30pm - “Beyond the dome: innovating lung research with next-generation in vitro models” Salvatore Simmini, PhD Simmini, STEMCELL Technologies ⏰ 5pm - Networking, discussion and refreshments. Registration will open soon! To find out more visit https://ow.ly/w4QR50QAkto

#FlashbackFriday to earlier this week, when our Head of Communications Nikki Mann and Communications and Events Coordinator Mary-Jane Roebuck visited the Wellcome Sanger Institute. Big thank you to Alexandra Canet for the guided tour! It was fantastic to talk about community building and the opportunities and challenges of internal communication, and to share experiences and ideas from our two very different campuses – the Wellcome Genome Campus and Cambridge Biomedical Campus. If you're part of a local science park, campus, or incubator space and have ideas for community building, join us in the Space & Infrastructure Network (SPIN) network on Connect: Health Tech to share ideas: https://lnkd.in/gu-gXfjB

The July Milner newsletter has hit virtual stands! Follow the link below to view the latest issue, past issues, and to subscribe to future issues! This month ...   🎟️ Symposium photographs! #MilnerSymp24 🧪 Academic spotlight on Professor Menna Clatworthy 🔬 Affiliated Company spotlights on Domainex and Verinnogen 🧬 Functional Genomics Screening Laboratory 🌴 Connect: Health Tech    💡Highlighted Events https://lnkd.in/gaFDnDV

Earlier this month, Milner Head of Computational Biology and Artificial Intelligence Dr Namshik Han attended an AI Workshop with two companies in the Milner Therapeutics Consortium, AstraZeneca and Shionogi.   The workshop – held at the AZ Discovery Centre (DISC) on the Cambridge Biomedical Campus – focused on innovative AI applications in pharma research, and how AI fits into the DMTA (Design-Make-Test-Analyze) cycle.   Dr Namshik Han said:    “It was fantastic to discuss the uses and future potential of Artificial Intelligence in R&D, from large language models in pharma research to image and video analysis for drug evaluation and spatial omics for understanding diseases. We plan to keep the conversation going, and I look forward to working more with our partners over the coming months.” 👉 Read more about work in our Computational Biology and AI team here: https://lnkd.in/et4uiztM 👉 Read about the Milner Therapeutics Consortium here: https://lnkd.in/dq-sNSKd

Are you a clinician with an innovative idea? 💡 Join the Clinical Innovators Network to explore videos that are by clinicians, for clinicians. First up, Louise Allen, Consultant Paediatric Ophthalmologist at Cambridge University Hospitals NHS Foundation Trust, and Amit Agrawal, Consultant Oncoplastic Breast Surgeon, share their experiences of early-stage discussions, roadblocks and support available. 🌟 Explore video resources by clinicians, for clinicians. 🌟 Connect with other clinicians. 🌟 Seek advice from a network of innovation facilitators. 👉 https://lnkd.in/e9Nbkvqa

Earlier this year, our Head of Research Dr Nicola McCarthy sat down with Megan Thomas, Multimedia Editor at Drug Discovery World, to explore Nicola’s role at the MTI, her career journey, and her views on the current opportunities and challenges in the field of drug discovery. Nicola oversees the wet and dry labs of our Institute, where we are developing our own research programme and target discovery pipeline. The methods and approaches being used are disease-agnostic and we are currently applying these in oncology, respiratory disease, metabolic disorders, infectious disease, inflammatory bowel disease and CNS diseases. Did you know we have three research groups at the MTI? 🧫 The Target Discovery Team led by Dr Erica Bello https://lnkd.in/eUtETnky 🤖 The Computational Research and Artificial Intelligence team led by Dr Namshik Han https://lnkd.in/et4uiztM 🧬 The Functional Genomics Screening Laboratory, led by Drs Chun Hao Wong and Ulrike Künzel https://lnkd.in/eY_PhHqB Read more and watch Nicola's interview via our website: https://lnkd.in/efqEbNjr #MilnerMonday #drugdiscovery #careersinscience #womeninstem

📣The next Cambridge New Therapeutics Forum (CamNTF) event is being hosted by European Bioinformatics Institute | EMBL-EBI on Tuesday 16th July! The meeting will explore the latest advancements in the field of therapeutics, and is open to all scientists researching new therapeutics in Cambridge and the local area. Registration 👉 https://lnkd.in/e5Hgsexf Event Partners: European Bioinformatics Institute | EMBL-EBI, Astex Pharmaceuticals , One Nucleus, The Babraham Institute, AstraZeneca, Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge